Discovery phase bioanalysis services including rapid screening, non-GLP bioanalysis tailored to support your early-stage drug development and lead optimization

We deliver high-quality data faster, without sacrificing its usability or quality. Intertek provides three 'standard' modes of LC-MS/MS bioanalytical support for drug discovery based upon your requirements. A dedicated LC-MS/MS discovery project team typically delivers data within five days after sample receipt, given one-week of advance notice.

Mode I - Rapid Discovery Screen

  • Optimize instrument, run curve and samples directly using a generic method without prior assessment.

Mode II – Lead Optimization (non-GLP early Pharmacokinetic (PK) studies)

  • Set up and run an extracted curve (protein ppt. or other extraction methods as needed) and QC spikes to evaluate method performance and range (Day 1)
  • Assay samples with freshly prepared curve (n=2 at each concentration) and QC spikes (Day 2)

Mode III – Lead Qualification (bridging and non-GLP toxicokinetic studies)

  • Intra-assay precision and accuracy QCs (n=5 at low, mid and high)
  • Lower limit of quantitation - LLOQ (n=5)
  • Room temperature matrix stability (n=3)
  • Room temperature extract stability (re-injection of curve and QC's)  

Total Quality Assurance for Bioanalysis Discovery Programs
    With the integration of advanced analytical technologies and a heritage supporting bio/pharmaceutical product development, our lab experts provide Total Quality Assurance (TQA) to help you ensure data accuracy and reliability. Intertek's innovative and global pharmaceutical services bring quality, safety, and sustainability to life.
    Need help or have a question?

    Related Links

    Discover our services

    • In vitro Toxicology Screening Services to Help Minimise Liabilities and Inform Drug Development Strategies
      Learn more 
    • Drug Tolerance Assessment and Improvement in Cell Based NAb Assays Using Response Data Modeling
      Learn more
    • Bioanalysis and Toxicology Challenges with ADC: How are They Different and New?
      Hosted by the Bioanalysis Zone
      Learn More
    • Overcoming Challenges in the Development and Validation of Biologics and Small Molecules in Ocular Tissues
      Hosted by the Bioanalysis Zone
      Learn more
    • Impact of Recent Changes to FDA Immunogenicity Draft Guidance
      Hosted by the Bioanalysis Zone
      Learn more
    • Additional webinars
    Contact Intertek